N'-((1E)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5497124 |
| CHEMBL ID | 192509 |
| CHEBI ID | 93087 |
| SCHEMBL ID | 1131313 |
| MeSH ID | M0486385 |
| Synonym |
|---|
| AKOS001103843 |
| c18h21n3o2 |
| BRD-K62353524-001-01-8 |
| gsk 9089 |
| gsk9089 |
| n''-[(1e)-[4-(diethylamino)phenyl]methylidene]-4-hydroxybenzohydrazide |
| bdbm22439 |
| 95167-41-2 |
| NCGC00092349-02 |
| NCGC00092349-01 |
| n'-((1e)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazide |
| dy131 |
| CHEMBL192509 |
| n-[(e)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide |
| HY-15483 |
| dy 131 |
| 5vwv92039e , |
| benzoic acid, 4-hydroxy-, ((4-(diethylamino)phenyl)methylene)hydrazide |
| unii-5vwv92039e |
| benzoic acid, 4-hydroxy-, 2-((4-(diethylamino)phenyl)methylene)hydrazide |
| gsk-9089 |
| benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide |
| S5364 |
| SCHEMBL1131313 |
| n-(4-(diethylaminobenzylidenyl)-n'-(4-hydroxybenzoyl)-hydrazine |
| AC-35431 |
| n-(4-(diethylaminobenzylidenyl)-n'-( 4-hydroxybenzoyl)-hydrazine |
| HB2491 |
| mfcd00715585 |
| EX-A121 |
| n'-{[4-(diethylamino)phenyl]methylidene}-4-hydroxybenzohydrazide |
| CHEBI:93087 |
| dy 131, >=98% (hplc) |
| (e)-n'-(4-(diethylamino)benzylidene)-4-hydroxybenzohydrazide |
| Z49615781 |
| n'-(4-(diethylamino)benzylidene)-4-hydroxybenzohydrazide |
| HMS3677A06 |
| (e)-dy131 |
| 849764-85-8 |
| HMS3413A06 |
| CCG-267593 |
| (e)-n'-[4-(diethylamino)benzylidene]-4-hydroxybenzohydrazide |
| AS-55821 |
| VDA16741 |
| n'-[(e)-[4-(diethylamino)phenyl]methylidene]-4-hydroxybenzohydrazide |
| EN300-21038927 |
| (e)-n'-(4-(diethylamino) benzylidene)-4-hydroxybenzohydrazide |
| EN300-1700019 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 14.1254 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 20.4839 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 20.4839 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 7.0795 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.1623 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 10.2663 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 1.4602 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 6.3096 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Estrogen-related receptor gamma | Homo sapiens (human) | IC50 (µMol) | 0.6600 | 0.0020 | 0.2273 | 2.0000 | AID241851 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Estrogen-related receptor gamma | Homo sapiens (human) | EC50 (µMol) | 0.1300 | 0.0150 | 0.6649 | 1.8990 | AID1798195; AID246440 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID251175 | Estrogen-Related Receptor gamma activity in FRET assay | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9 | Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. |
| AID246440 | Estrogen-Related Receptor gamma activity in FRET assay | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9 | Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. |
| AID241851 | Inhibition of [3H]4-OHT binding to Estrogen-Related Receptor gamma | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9 | Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. |
| AID1798195 | ERRgamma FRET Assay from Article 10.1021/jm050161j: \\Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.\\ | 2005 | Journal of medicinal chemistry, May-05, Volume: 48, Issue:9 | Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||